Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Nov 22, 2025
- Amount
- $700,000
- Closes
- Feb 9, 2027 (in 122 days)
Similar opportunities open now
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 10, 2026 (in 31 days)Up to $300K
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 10, 2026 (in 31 days)Up to $150K
- Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Sep 2028Up to $1.8M
- Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Jan 2027
- CCRP Initiative: Promoting a Basic Understanding of Chemical Threats to Skin (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Nov 2028Up to $300K
Classification and identifiers
- Solicitation number
- RFA-CA-28-013
- Assistance listing (CFDA)
- 93.399
Amount
$700,000
Who can apply
Public colleges and universities can apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications to critically and systematically evaluate the scientific evidence on carcinogenic hazards to humans. Identifying potential carcinogens is essential for guiding and advancing cancer research, as well as informing cancer control and prevention efforts. The resulting monographs will serve as crucial references that shape health policy and regulation, ultimately helping to reduce the cancer burden for all